[{"orgOrder":0,"company":"Mediolanum Farmaceutici","sponsor":"ElsaLys Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mediolanum Farmaceutici","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mediolanum Farmaceutici \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Mediolanum Farmaceutici \/ Mediolanum Farmaceutici"}]

Find Clinical Drug Pipeline Developments & Deals by Mediolanum Farmaceutici

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Acquisition of ElsaLys Biotech adds drugs like Inolimomab and ELB011 to Mediolanum Farmaceutici's pipeline paving the way for its international expansion and increasing the Group's R&D capabilities.

                          Product Name : Leukotac

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 05, 2020

                          Lead Product(s) : Inolimomab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Recipient : ElsaLys Biotech

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank